A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
NCT05217355
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Glabellar Frown Lines
Interventions
DRUG:
MBA-P01 (Botulinum toxin A)
DRUG:
Placebo
Sponsor
Medytox Korea